BioNTech SE (BNTX)
142.06
-2.34 (-1.62%)
USD |
NASDAQ |
Feb 03, 16:00
142.59
+0.53 (+0.37%)
After-Hours: 19:59
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 34.48B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -17.74% |
Valuation | |
PE Ratio | 3.243 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 1.804 |
Price to Book Value | 1.910 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 2.132 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.0149 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
02/03 11:34
MT Newswires
02/02 10:17
Yahoo
02/02 09:25
Globe Newswire
02/02 06:45
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
03/30/2023* | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
03/30/2023* | -- | Results | Q4 2022 | -- | 8.57 | -- | |
11/07/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/07/2022 | -- | Results | Q3 2022 | 6.93 | 3.39 | 104.3% | |
08/08/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
08/08/2022 | -- | Results | Q2 2022 | 6.56 | 7.19 | -8.76% | |
05/09/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
05/09/2022 | -- | Results | Q1 2022 | 15.00 | 9.62 | 55.85% |
*Estimated Date/Time
Earnings
Profile
Edit
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product. |
URL | https://www.biontech.de |
Investor Relations URL | https://investors.biontech.de/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 30, 2023 (est.) |
Last Earnings Release | Nov. 07, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 02, 2022 |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | 2.132 |
Dividend Frequency | Annually |
Last Ex-Dividend Date | Jun. 02, 2022 |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | 4.30% |
Cash Payout Ratio | 3.96% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
Revenue (TTM) | 20.37B |
Total Expenses (TTM) | 5.589B |
Net Income (TTM) | 11.35B |
Total Assets (Quarterly) | 22.27B |
Total Liabilities (Quarterly) | 4.221B |
Shareholders Equity (Quarterly) | 18.05B |
Cash from Operations (TTM) | 12.61B |
Cash from Investing (TTM) | 6.505M |
Cash from Financing (TTM) | -1.422B |
Ratings
Profile
Edit
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product. |
URL | https://www.biontech.de |
Investor Relations URL | https://investors.biontech.de/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 30, 2023 (est.) |
Last Earnings Release | Nov. 07, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Jun. 02, 2022 |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Top Fund Holders
Symbol | Dollars Invested | % Weight |
---|---|---|
GNOM | 9.063M USD | 3.91% |
BBH | 20.73M USD | 3.86% |
F00001DVDD | 369181.0 USD | 3.69% |
F00001EN98 | 366683.0 USD | 3.67% |
IDNA | 5.926M USD | 3.54% |
FBT | 50.63M USD | 3.29% |
FNRTYX | 320251.0 USD | 3.20% |
BGLFX | 16.17M USD | 3.18% |
POAGX | 192.00M USD | 2.85% |
IBB | 213.26M USD | 2.34% |
VHCOX | 285.76M USD | 1.69% |
HQL | 5.586M USD | 1.42% |
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
BNTX Tweets |